COPD – Medxy AI

Technical and Clinical Feasibility of a Pulmonary Telerehabilitation Model for People with COPD: A Comprehensive Review

By MedXY 10/18/2026

This review synthesizes evidence on the feasibility, acceptance, and clinical outcomes of pulmonary telerehabilitation models in COPD, highlighting technical reliability, patient adherence, and clinical benefits from recent trials, including the novel HBPR application study (NCT05314686).

Clinical Updates news Respiratory

Sputum Cellularity and Health Services Utilization in Asthma and COPD: Insights into Inflammatory Phenotypes and Clinical Outcomes

By MedXY 10/08/2026

Sputum eosinophilia is linked to increased asthma-specific health services use, while neutrophilic inflammation drives hospitalizations in COPD. Understanding these inflammatory patterns aids personalized management and resource planning.

news Respiratory

Airway Mucus Plugs on CT: Predicting Respiratory Outcomes in COPD and Preserved Spirometry — Insights from a Chinese Cohort

By MedXY 09/30/2026

This prospective Chinese cohort study found that airway mucus plugs on chest CT are linked to increased risk of exacerbations and COPD development, even in individuals with preserved spirometry, highlighting their prognostic value in early COPD detection and management.

news Respiratory

Predicting Lung Function Decline in COPD via One-Year CT Emphysema Subtype Progression: Insights from SPIROMICS

By MedXY 09/29/2026

SPIROMICS study demonstrates that progression of CT-detected emphysema subtypes over one year independently predicts accelerated FEV₁ decline, offering valuable intermediate endpoints for COPD clinical trials.

Diabetes & Endocrinology news Respiratory

Comparative Skeletal Risks of COPD and Type 2 Diabetes Mellitus: Insights from a Nationwide Propensity-Matched Cohort

By MedXY 09/27/2026

This study reveals that COPD poses a greater risk to bone health than T2DM, with combined COPD and T2DM further increasing osteoporosis and fracture risk, especially in men, emphasizing the need for targeted bone health screening.

news Respiratory

Innovative Cryospray Therapy Shows Promise for Chronic Bronchitis in COPD Patients: Insights from the SPRAY-CB Trial

By MedXY 09/26/2026

Metered-dose liquid nitrogen cryospray significantly improves quality of life and reduces severe exacerbations in COPD patients with chronic bronchitis, with a favorable safety profile demonstrated in a recent sham-controlled trial.

Clinical Updates news Respiratory

Mixed Mucus Plug-Emphysema Subtype and Acute Exacerbation in Chronic Obstructive Pulmonary Disease: A Quantitative CT Phenotyping Approach

By MedXY 09/25/2026

Quantitative CT-defined mucus plugs combined with emphysema severity stratify COPD patients into distinct subtypes that predict risk of acute exacerbations, enabling personalized risk assessment and targeted preventive strategies.

Clinical Updates news Radiology Respiratory

Quantitative CT-Based Mixed Mucus Plug-Emphysema Phenotyping Predicts Exacerbation Risk in COPD: Integrating Imaging Biomarkers for Precision Medicine

By MedXY 09/24/2026

This review synthesizes recent evidence on quantitative CT markers of mucus plugging and emphysema in COPD, highlighting their combined impact on acute exacerbation risk and clinical heterogeneity, and discusses implications for personalized risk stratification and therapeutic targeting.

Clinical Updates news Respiratory

Astegolimab for Chronic Obstructive Pulmonary Disease with Frequent Exacerbations: Insights from the Pooled ALIENTO and ARNASA Trials

By MedXY 09/13/2026

Astegolimab, an anti-ST2 monoclonal antibody, significantly reduced moderate/severe exacerbations in COPD patients with frequent exacerbations in pooled ALIENTO and ARNASA analyses, showing promise for targeting the IL-33/ST2 pathway with good safety.

news Respiratory

Efficacy of Dupilumab in Reducing COPD Exacerbations, Emergency Department Visits, and Corticosteroid Use: Insights from a Pooled Phase 3 Analysis

By MedXY 09/12/2026

Dupilumab significantly reduces emergency visits, hospital admissions, and systemic corticosteroid use in COPD patients with type 2 inflammation, offering a promising therapeutic option to mitigate exacerbation-associated morbidity.

news Respiratory

Defining and Achieving Disease Stability in COPD: Insights from Phase 3 Trials

By MedXY 09/09/2026

This article explores disease stability as a key treatment target in COPD, analyzing major phase 3 trials that show stability predicts reduced exacerbations and mortality, supporting its use to guide therapy.

news Respiratory

Comparative Efficacy of Mepolizumab and Dupilumab in Eosinophilic COPD: Insights from a Matching-Adjusted Indirect Treatment Comparison

By MedXY 08/23/2026

A recent MAIC study comparing mepolizumab and dupilumab in eosinophilic COPD patients found no significant difference between the treatments in reducing exacerbations or improving quality of life.

news Respiratory

Refining COPD Exacerbation Risk Categories Enhances Prediction of Future Episodes

By MedXY 08/20/2026

A recent study demonstrates that defining COPD exacerbation risk by any moderate or severe event over two years improves prediction accuracy and clinical decision-making compared to the standard one-year criteria.

Cardiology news Respiratory

Unraveling the Mortality Benefits of Beta-Blockers in COPD Patients with Cardiovascular Disease: Influence of LABA Co-therapy

By MedXY 08/12/2026

A large UK cohort study reveals that beta-blockers reduce mortality in COPD patients with heart failure or ischemic heart disease, but concurrent long-acting beta-agonists may attenuate this benefit.

Allergy & Immunology news Respiratory

Decoding the Immune Landscape of COPD: Single-Cell RNA Sequencing Reveals Profibrotic Macrophage and Monocyte Niches Driving Disease Progression

By MedXY 08/04/2026

This study uses single-cell RNA sequencing of bronchoalveolar lavage cells to reveal immune dysregulation in COPD, highlighting profibrotic macrophages and monocytes as key players in airway remodeling and gas exchange impairment.

Clinical Updates news Respiratory

Prognostic Impact of Single Moderate Exacerbation in COPD Patients: Insights from 12-Year Mortality and Future Exacerbation Risk Analysis

By MedXY 08/02/2026

A single moderate COPD exacerbation markedly increases future exacerbation risk and long-term mortality, justifying its reclassification as high risk per GOLD 2026 guidelines and supporting refined risk stratification for better clinical management.

Clinical Updates Internal Medicine news

Mosaic Loss of Y Chromosome Links to Pulmonary Decline, Emphysema, and Accelerated Epigenetic Aging in Men: A Comprehensive Review

By MedXY 07/15/2026

Mosaic loss of Y chromosome (mLOY) in men is strongly associated with diminished lung function, increased emphysema severity, and faster epigenetic aging, positioning mLOY as a novel biomarker for respiratory aging and COPD risk in males.

Cardiology news Respiratory

Enhancing Risk Prediction After TAVI: The COPD-Augmented R₂CHA₂DS₂-VA Score and Its Prognostic Value

By MedXY 07/03/2026

A novel risk score incorporating COPD and graded renal dysfunction improves prediction of one-year mortality post-TAVI, showing excellent internal validity but requiring external validation before clinical use.

Family Medicine & Nutrition news Respiratory

Empowering Climate-Conscious Inhaler Prescribing: A Patient-Physician Conversation Aid

By MedXY 06/30/2026

A novel conversation aid was developed and refined iteratively with patients and physicians to support shared decision-making for low carbon footprint inhaler prescribing in asthma and COPD, balancing environmental impact with safety and patient preferences.

news Respiratory

Mepolizumab and Blood Eosinophil Variability in COPD: A New Dimension in Targeted Therapy

By MedXY 06/13/2026

This article reviews mepolizumab efficacy in COPD patients with variable blood eosinophil counts, showing benefits even with intermittent eosinophilia, expanding treatable phenotypes beyond persistent elevation.